Evorpacept's Positive Clinical Trial Results
Evorpacept showed a significant benefit in HER2-positive gastric cancer patients with high CD47 expression, achieving a 65% ORR in the treatment arm versus 26% in control, and a median PFS of 18.4 months compared to 7 months in control.
Strong Financial Position
The company reported a total cash balance of $67 million, expected to provide runway into the first quarter of 2027.
ALX2004 Clinical Progress
The EGFR-targeted ADC, ALX2004, is progressing well in clinical trials, with the first dose cohort completed without any DLT and currently dosing in the second cohort.